» Articles » PMID: 38172503

ITGB4 Upregulation is Associated with Progression of Lower Grade Glioma

Overview
Journal Sci Rep
Specialty Science
Date 2024 Jan 3
PMID 38172503
Authors
Affiliations
Soon will be listed here.
Abstract

Gliomas originating in the neuroepithelium account for about 80% of brain malignancies and are the most common cancer of the central nervous system. Clinical management of gliomas remains challenging despite significant advances in comprehensive therapies, including radiotherapy, chemotherapy, and surgery. The ITGB4 (Integrin subunit beta 4) gene encodes a receptor for laminins and its upregulation in tumor tissues is associated with poor prognosis. However, its role in glioma is not well understood. First, we performed a pan cancer analysis of ITGB4 expression in The Cancer Genome Atlas (TCGA) dataset. Survival analysis was done on Chinese Glioma Genome Atlas (CGGA) and TCGA. Immunohistochemistry was then used to validate the expression and role of ITGB4 in glioma. We finally analyzed the possible mechanism by immune infiltration and single-cell sequencing analysis. Here, we found that ITGB4 is upregulated in glioma and accurately predicts the prognosis of lower grade glioma (LGG). Univariate and multivariate Cox regression analyses showed that ITGB4 is a risk factor for LGG. Immunohistochemical analysis confirmed that ITGB4 accurately predicts LGG prognosis. Non-negative matrix factorization (NMF) cluster analysis showed that ITGB4 was closely related to immune related genes. Immune cell infiltration and single cell sequencing analyses indicated that ITGB4 may be closely related to the microenvironment of gliomas, especially tumor-associated fibroblasts. ITGB4 is a promising diagnostic and therapeutic factor in LGG patients.

Citing Articles

The mechanism of ITGB4 in tumor migration and invasion.

Huang G, Zhou M, Lu D, Li J, Tang Q, Xiong C Front Oncol. 2024; 14:1421902.

PMID: 39169946 PMC: 11335651. DOI: 10.3389/fonc.2024.1421902.

References
1.
Wu J, Zhao R, Lin J, Liu B . Integrin β4 reduces DNA damage‑induced p53 activation in colorectal cancer. Oncol Rep. 2018; 40(4):2183-2192. DOI: 10.3892/or.2018.6628. View

2.
Xiong Z, Xiong Y, Liu H, Li C, Li X . Identification of purity and prognosis-related gene signature by network analysis and survival analysis in brain lower grade glioma. J Cell Mol Med. 2020; 24(19):11607-11612. PMC: 7576230. DOI: 10.1111/jcmm.15805. View

3.
Gan L, Meng J, Xu M, Liu M, Qi Y, Tan C . Extracellular matrix protein 1 promotes cell metastasis and glucose metabolism by inducing integrin β4/FAK/SOX2/HIF-1α signaling pathway in gastric cancer. Oncogene. 2017; 37(6):744-755. DOI: 10.1038/onc.2017.363. View

4.
Ruan S, Lin M, Zhu Y, Lum L, Thakur A, Jin R . Integrin β4-Targeted Cancer Immunotherapies Inhibit Tumor Growth and Decrease Metastasis. Cancer Res. 2019; 80(4):771-783. PMC: 7024642. DOI: 10.1158/0008-5472.CAN-19-1145. View

5.
Yoshioka T, Otero J, Chen Y, Kim Y, Koutcher J, Satagopan J . β4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest. 2013; 123(2):682-99. PMC: 3561800. DOI: 10.1172/JCI60720. View